Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ETON | CLUSTER | neutral | 4/10 | Two Eton Pharmaceuticals insiders (a director and the Chief Business Officer) sold a combined $2.44M in shares over a on | Aug 31, 2026 |
| RLAY | CLUSTER | bearish | 6/10 | Two insiders at Relay Therapeutics sold a combined $116.49M in shares over a 7-day window. The overwhelming majority ($1 | Aug 29, 2026 |
| MEDP | CLUSTER | neutral | 4/10 | A significant insider selling cluster at Medpace (MEDP) totaling $14.45M over a 7-day window, led by CEO August Troendle | Aug 29, 2026 |
| OMER | CLUSTER | neutral | 5/10 | Three OMER insiders, including two directors and the VP of Finance, sold a total of ~$387K in open-market shares over a | Aug 29, 2026 |
| CORT | CLUSTER | neutral | 2/10 | Two Corcept Therapeutics insiders — Director Kimberly Park and executive Sean Maduck — sold a combined $4.01M in open-ma | Aug 29, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt executed a large derivative exercise of 9,500 shares at $135.42, then immediately sold the resulti | Aug 29, 2026 |
| PGEN | CLUSTER | neutral | 3/10 | A mixed insider cluster at Precigen shows a director selling $1.38M in open-market shares and the CCO selling $594K post | Aug 28, 2026 |
| MNPR | CLUSTER | neutral | 2/10 | Three Monopar insiders (two directors and one insider) sold a total of ~$257K in open-market sales over a two-day window | Aug 28, 2026 |
| ATTO | 144, CLUSTER | neutral | 3/10 | Goldman Sachs Group Inc., a former 10% owner of Attovia Therapeutics, filed a Form 144 notice of intent to sell 105,807 | Aug 28, 2026 |
| ETON | CLUSTER | neutral | 4/10 | Two Eton insiders, including the Chief Business Officer and a Director, sold a combined $2.44M in open-market sales over | Aug 28, 2026 |
| BMRA | CLUSTER | mixed | 6/10 | Biomerica insiders, including the CEO and Executive Vice Chairman, made open-market purchases totaling $158K on August 2 | Aug 28, 2026 |
| MEDP | CLUSTER | neutral | 3/10 | Four Medpace insiders, including the CEO, CFO, and two directors, sold a total of $10.0M in shares over a one-week windo | Aug 28, 2026 |
| QTTB | CLUSTER | neutral | 2/10 | Q32 Bio CEO and CFO sold a combined $229K in open-market sales on August 25, 2026, at $16.56 per share. The total value | Aug 28, 2026 |
| TWST | CLUSTER | neutral | 4/10 | A cluster of insider selling at Twist Bioscience, led by CEO Emily Leproust selling ~$6.3M in open-market transactions o | Aug 28, 2026 |
| CSTL | CLUSTER | neutral | 4/10 | Two C-suite insiders at Castle Biosciences sold a combined $498K in open-market transactions over two days, with the COO | Aug 28, 2026 |
| CRL | CLUSTER | neutral | 3/10 | Two CRL insiders sold a total of ~$763K in open-market shares over the past week, while Director James C. Foster exercis | Aug 28, 2026 |
| CORT | CLUSTER | neutral | 2/10 | Two Corcept Therapeutics insiders sold a total of ~$788K in shares over a week, with the bulk ($740K) from Sean Maduck ( | Aug 28, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined ~$388K in open-market UTHR shares over the past week, with Roth | Aug 28, 2026 |
| MNPR | CLUSTER | neutral | 3/10 | Two Monopar Therapeutics directors sold a total of $144K in open-market sales over a two-day window, with Kim Tsuchimoto | Aug 27, 2026 |
| GILD | CLUSTER | neutral | 2/10 | Two GILD directors sold a combined $926K in open-market sales over a one-week window. Director Anthony Welters executed | Aug 27, 2026 |
| RAPP | CLUSTER | neutral | 3/10 | Two top insiders at Rapport Therapeutics (CEO and Chief Development Officer) sold a combined ~$1.98M in open-market sale | Aug 27, 2026 |
| CSTL | CLUSTER | bearish | 5/10 | Two C-suite insiders at Castle Biosciences sold a combined $463K in open-market sales over a week, with the COO alone se | Aug 27, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt executed a large cluster of open-market sales totaling approximately $12.5M over Aug 21-25, alongs | Aug 27, 2026 |
| TRDA | CLUSTER | neutral | 3/10 | Two MPM BioVentures funds, each a 10% owner of Entrada Therapeutics, sold a combined ~$400K in open-market sales over th | Aug 26, 2026 |
| IRON | CLUSTER | neutral | 3/10 | Two C-suite insiders at Disc Medicine (IRON) sold a total of $681K in open-market sales over a one-week window, with CEO | Aug 26, 2026 |
| OCUL | CLUSTER | neutral | 3/10 | Four OCUL insiders, including the Chief Scientific Officer and Chief Strategy Officer, sold a total of $322K in open-mar | Aug 26, 2026 |
| LYEL | CLUSTER | neutral | 4/10 | Three top executives at Lyell Immunopharma (CEO, CSO, COO) sold a combined $187K in stock on the same day (Aug 21, 2026) | Aug 26, 2026 |
| LQDA | CLUSTER | neutral | 3/10 | Two Liquidia insiders — the Chief Medical Officer and a Director — sold a combined $5.03M in open-market stock over thre | Aug 26, 2026 |
| TEVA | CLUSTER | neutral | 2/10 | Two Teva insiders — a director and an EVP — sold a combined $696K in open-market sales over a one-week window. The EVP's | Aug 26, 2026 |
| RVMD | CLUSTER | neutral | 3/10 | Two insiders at Revolution Medicines — General Counsel Jeff Cislini and Director Mark Goldsmith — sold a combined ~$22.5 | Aug 26, 2026 |